Careers  |  Sign In  |  Register  |   Twitter

AstraZeneca Immuno-Oncology Treatment Enters Phase II Trial

MEDI-4736, AstraZeneca‘s new immuno-oncology drug will be tested in a Phase II trial in 48 patients with colorectal cancer, Reuters article reports. The drug is designed to help the immune system fight tumors, and is currently being studied in lung, as well as head and neck cancer. AstraZeneca shares rose 2.1 percent, as MEDI-4736 is forecasted to make $6.5 billion in sales, as the new drug carries with it a great deal of hope for the future of the company.

Read the article published by Reuters.